Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift

References

• Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021;384:238–13.
   PubMed Web of Science ®Google Scholar
• Libster R, Perez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT, Wood C, Berrueta M. Early high-titer plasma therapy to prevent severe covid-19 in older adults. N Engl J Med. 2021;384(7):610–18. doi:10.1056/NEJMoa2033700.
   PubMed Web of Science ®Google Scholar
• Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19. N Engl J Med. 2021;384(3):229–37. doi:10.1056/NEJMoa2029849.
   PubMed Web of Science ®Google Scholar
• Raybould MIJ, Kovaltsuk A, Marks C, Deane CM, Wren J. CoV-AbDab: the coronavirus antibody database. Bioinformatics. 2020;37(5):734–35. doi:10.1093/bioinformatics/btaa739.
   Google Scholar
• Starr TN, Czudnochowski N, Liu Z, Zatta F, Park YJ, Addetia A, Pinto D, Beltramello M, Hernandez P, Greaney AJ. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature. 2021;597(7874):97–102. doi:10.1038/s41586-021-03807-6.
   PubMed Web of Science ®Google Scholar
• Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann -H-H, Michailidis E. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9. doi:10.7554/eLife.61312
   PubMed Web of Science ®Google Scholar
• Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, Liu J, Errico, JM, Xie X, Suryadevara N, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–26. doi:10.1038/s41591-021-01294-w.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–35. doi:10.1038/s41586-021-03398-2.
   PubMed Web of Science ®Google Scholar
• Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29(3):477–88.e4. doi:10.1016/j.chom.2021.01.014.
   PubMed Web of Science ®Google Scholar
• Kistler KE, Bedford T. Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229e. eLife. 2021;10:e64509. doi:10.7554/eLife.64509.
   PubMed Web of Science ®Google Scholar
• Eguia RT, Crawford KHD, Stevens-Ayers T, Kelnhofer-Millevolte L, Greninger AL, Englund JA, Boeckh MJ, Bloom JD. A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 2021;17(4):e1009453. doi:10.1371/journal.ppat.1009453.
   PubMed Web of Science ®Google Scholar
• Starr TN, Greaney AJ, Dingens AS, Bloom JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021;2(4):100255. doi:10.1016/j.xcrm.2021.100255.
   PubMedGoogle Scholar
• Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463–76.e6. doi:10.1016/j.chom.2021.02.003.
   PubMed Web of Science ®Google Scholar
• Widera M, Wilhelm A, Hoehl S, Pallas C, Kohmer N, Wolf T, Rabenau HF, Corman V, Drosten C, Vehreschild M, et al. Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro. medRxiv. February 24 2021;2021: 21252372.
   Google Scholar
• Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–80. doi:10.1038/s41586-021-03777-9.
   PubMed Web of Science ®Google Scholar
• Lv H, Wu NC, Tsang OT, Yuan M, Perera R, Leung WS, So RTY, Chan JMC, Yip GK, Chik TSH, et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 2020;31(9):107725. doi:10.1016/j.celrep.2020.107725.
   PubMed Web of Science ®Google Scholar
• Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–95. doi:10.1038/s41586-020-2349-y.
   PubMed Web of Science ®Google Scholar
• Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L, Hoffmann M, Pöhlmann S, et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell. 2020;181(5):1004–15 e15. doi:10.1016/j.cell.2020.04.031.
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115–19. doi:10.1038/s41586-020-2380-z.
   PubMed Web of Science ®Google Scholar
• Bates TA, Weinstein JB, Farley S, Leier HC, Messer WB, Tafesse FG. Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2. Cell Rep. 2021;34(7):108737. doi:10.1016/j.celrep.2021.108737.
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus A, van Kuppeveld FJM, Haagmans BL, Grosveld F, Bosch B-J. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251. doi:10.1038/s41467-020-16256-y.
   PubMed Web of Science ®Google Scholar
• Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakharkar M, Huang D, Deveau LM, Yockachonis TJ, Herbert AS, Battles MB, et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021;371(6531):823. doi:10.1126/science.abf4830.
   PubMed Web of Science ®Google Scholar
• Schepens B, van Schie L, Nerinckx W, Roose K, Van Breedam W, Fijalkowska D, Devos S, Weyts W, De Cae S, Vanmarcke S. An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. Sci Transl Med. 2021;13(621):eabi7826. doi:10.1126/scitranslmed.abi7826.
   PubMed Web of Science ®Google Scholar
• Jacobs TM, Yumerefendi H, Kuhlman B, Leaver-Fay A. SwiftLib: rapid degenerate-codon-library optimization through dynamic programming. Nucleic Acids Res. 2015;43(5):e34. doi:10.1093/nar/gku1323.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Tang Y, L-L A, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol. 2005;350(1):126–44. doi:10.1016/j.jmb.2005.04.049.
   PubMed Web of Science ®Google Scholar
• Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science (New York, N.Y.). 2016;351(6279):1339–42. doi:10.1126/science.aad5224.
   PubMed Web of Science ®Google Scholar
• Nathan R, Shawa I, De La Torre I, Pustizzi JM, Haustrup N, Patel DR, Huhn G. A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2. Infect Dis Ther. 2021;10(4):1933–47. doi:10.1007/s40121-021-00515-6.
   PubMed Web of Science ®Google Scholar
• Corti D, LisaPurcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(12):3086–3108.
   PubMed Web of Science ®Google Scholar
• Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WG, Porrot F, Staropoli I, Lemoine F, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2021;602(7898): 671–375.
   PubMed Web of Science ®Google Scholar
• Touret F, Baronti C, Bouzidi HS, de Lamballerie X. In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. Sci Rep. January 1 2022;12(1):4683.
   PubMed Web of Science ®Google Scholar
• Simons JF, Lim YW, Carter KP, Wagner EK, Wayham N, Adler AS, Johnson DS. Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR. mAbs. 2020;12(1):1803646. doi:10.1080/19420862.2020.1803646.
   PubMed Web of Science ®Google Scholar
• Packer MS, Liu DR. Methods for the directed evolution of proteins. Nat Rev Genet. 2015;16(7):379–94. doi:10.1038/nrg3927.
   PubMed Web of Science ®Google Scholar
• Rajpal A, Beyaz N, Haber L, Cappuccilli G, Yee H, Bhatt RR, Takeuchi T, Lerner RA, Crea R. A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci U S A. 2005;102(24):8466–71. doi:10.1073/pnas.0503543102.
   PubMed Web of Science ®Google Scholar
• Skamaki K, Emond S, Chodorge M, Andrews J, Rees DG, Cannon D, Popovic B, Buchanan A, Minter RR, Hollfelder F. In vitro evolution of antibody affinity via insertional scanning mutagenesis of an entire antibody variable region. Proc Natl Acad Sci U.S.A. 2020;117(44):27307–18. doi:10.1073/pnas.2002954117.
   PubMed Web of Science ®Google Scholar
• Maynard JA, Maassen CBM, Leppla SH, Brasky K, Patterson JL, Iverson BL, Georgiou G. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol. 2002;20(6):597–601. doi:10.1038/nbt0602-597.
   PubMed Web of Science ®Google Scholar
• Zupancic JM, Desai AA, Schardt JS, Pornnoppadol G, Makowski EK, Smith MD, Kennedy AA, Garcia de Mattos Barbosa M, Cascalho M, Lanigan TM. Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis. Cell Chem Biol. 2021;28(9):1379–1388.e7. doi:10.1016/j.chembiol.2021.05.019.
   PubMed Web of Science ®Google Scholar
• Schoof M, Faust B, Saunders RA, Sangwan S, Rezelj V, Hoppe N, Boone M, Billesbølle CB, Puchades C, Azumaya CM. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370(6523):1473–79. doi:10.1126/science.abe3255.
   PubMed Web of Science ®Google Scholar
• Rouet R, Mazigi O, Walker GJ, Langley DB, Sobti M, Schofield P, Lenthall H, Jackson J, Ubiparipovic S, Henry JY. Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies. mAbs. 2021;13(1):1922134. doi:10.1080/19420862.2021.1922134.
   PubMed Web of Science ®Google Scholar
• Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, Navarro MJ, Bowen JE, Tortorici MA, Walls AC. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;182(5):1295–310 e20. doi:10.1016/j.cell.2020.08.012.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Starr TN, Barnes CO, Weisblum Y, Schmidt F, Caskey M, Gaebler C, Cho A, Agudelo M, Finkin S, et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun. 2021;12(1):4196. doi:10.1038/s41467-021-24435-8.
   PubMed Web of Science ®Google Scholar
• Zupancic JM, Schardt JS, Desai AA, Makowski EK, Smith MD, Pornnoppadol G, Garcia de Mattos Barbosa M, Cascalho M, Lanigan TM, Tessier JM, Engineered multivalent nanobodies potently and broadly neutralize SARS-CoV-2 variants. Adv Ther. 2021;4(8):2100099. doi:10.1002/adtp.202100099.
   Google Scholar
• Shrestha LB, Tedla N, Bull RA. Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants. Front Immunol. 2021;12(4025): 752003.
   PubMedGoogle Scholar
• Benatuil L, Perez JM, Belk J, Hsieh CM. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel. 2010;23(4):155–59. doi:10.1093/protein/gzq002.
   PubMed Web of Science ®Google Scholar
• Sivelle C, Sierocki R, Ferreira-Pinto K, Simon S, Maillere B, Nozach H. Fab is the most efficient format to express functional antibodies by yeast surface display. mAbs. 2018;10(5):720–729.
   PubMed Web of Science ®Google Scholar
• Hunter SA, Cochran JR. Cell-binding assays for determining the affinity of protein-protein interactions: technologies and considerations. Methods Enzymol. 2016;580:21–44.
   PubMed Web of Science ®Google Scholar
• Medina-Cucurella AV, Whitehead TA. Characterizing protein-protein interactions using deep sequencing coupled to yeast surface display. Methods Mol Biol. 2018;1764:101–21.
   PubMedGoogle Scholar
• Blankenberg D, Gordon A, Von Kuster G, Coraor N, Taylor J, Nekrutenko A Galaxy T, et al. Manipulation of FASTQ data with Galaxy. Bioinformatics. 2010;26(14):1783–85. doi:10.1093/bioinformatics/btq281.
   PubMed Web of Science ®Google Scholar
• Šali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234(3):779–815. doi:10.1006/jmbi.1993.1626.
   PubMed Web of Science ®Google Scholar
• Koenig PA, Das H, Liu H, Kummerer BM, Gohr FN, Jenster LM, Schiffelers LDJ, Tesfamariam YM, Uchima M, Wuerth JD, et al. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science. 2021;371(6530).
   Web of Science ®Google Scholar
• Phillips JC, Hardy DJ, Maia JDC, Stone JE, Ribeiro JV, Bernardi RC, Buch R, Fiorin G, Hénin J, Jiang W, et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. J Chem Phys. 2020;153(4):044130. doi:10.1063/5.0014475.
   PubMed Web of Science ®Google Scholar
• Huang J, MacKerell AD Jr. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem. 2013;34(25):2135–45. doi:10.1002/jcc.23354.
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14(1):33–38. doi:10.1016/0263-7855(96)00018-5.
   PubMedGoogle Scholar
• Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical-integration of cartesian equations of motion of a system with constraints - molecular-dynamics of N-Alkanes. J Comput Phys. 1977;23(3):327–41. doi:10.1016/0021-9991(77)90098-5.
   Web of Science ®Google Scholar
• Darden T, York D, Pedersen L. Particle mesh Ewald: an N.Log(N) Method for Ewald sums in large systems. J Chem Phys. 1993;98:10089–92. doi:10.1063/1.464397.
   Web of Science ®Google Scholar
• Brooks BR, Brooks CL 3rd, Mackerell AD Jr., Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, et al. CHARMM: the biomolecular simulation program. J Comput Chem. 2009;30(10):1545–614. doi:10.1002/jcc.21287.
   PubMed Web of Science ®Google Scholar